Niet eens zo lang geleden....
Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering (IPO) on Euronext Amsterdam
Jun 20, 2007
Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering (IPO) on Euronext Amsterdam
Highlights
Offer price of €10.00 per share
Issue of 5,000,000 new ordinary shares
Trading on Eurolist by Euronext expected to commence today as of 11:00a.m. Amsterdam time
Amsterdam, the Netherlands, 20 June 2007 - Amsterdam Molecular Therapeutics (AMT) Holding B.V. (to be converted today into a public company with limited liability, Amsterdam Molecular Therapeutics (AMT) Holding N.V.) ("AMT"), a Dutch company active in the field of human gene therapy, announces today that it shall issue 5,000,000 new ordinary shares with a nominal value of €0.04 each (the “Offer Shares”) for an offer price of €10.00 (the “Final Offer Price”) per share (the “Offering”), subject to the satisfaction of certain conditions on the settlement date of the Offering (which is expected to be on 25 June 2007). Based on the Final Offer Price and the issuance the Offer Price, AMT would have a market capitalisation on commencement of trading of approximately €139 million. Trading of the Offer Shares is expected to start today as of 11:00 a.m. Amsterdam time. ??Company overview?AMT is a biopharmaceutical company that develops gene-based therapies for orphan diseases. These diseases are associated with significant morbidity and mortality resulting in substantial costs to society, as about 6% to 8% of the total population in the Western world is affected by one of the circa 8,000 different orphan diseases that have been identified to date. About 80% of these identified orphan diseases are genetic disorders. By inserting the correct gene in the relevant tissues, our gene therapy products offer a long-term cure of the respective disease, whereas existing treatments only treat symptoms and subsequent medical complications.
AMT's product pipeline currently consists of six products in different stages of development. Its lead product, AMT-011 to treat LPL deficiency, a very serious and rare metabolic disease, is currently in pre-registration clinical trials. For this product AMT expects to file in Europe for market authorization in the first quarter of 2008, followed by a filing in the US and Canada.
All of the products in AMT's pipeline are based on its AAV (Adeno Associated Virus)-based gene insertion technology platform and its baculovirus based manufacturing platform. AMT is focusing on AAV, because of its proven safety. AMT genetically engineers AAV vectors to target various organs or specific tissues, such as muscle or liver, and even specific types of cells within these organs. By combining its AAV-based vectors with different therapeutic genes and tissue specific promoters, AMT has a platform vector technology that is modular in approach and this can facilitate fast product design timelines for its future products.
AMT's competitive strengths and attributes are as follows:
Delivery of a single-dose long-term cure for serious and rare diseases (orphan diseases);
Modular platform that can be applied to a large number of diseases;
Potential to shorten time-to-market because of R&D capabilities and processes as well as its orphan drug focus;
Collaborations with leading academic research groups fueling our future product pipeline; and
A proven ability to upscale the manufacturing of our lead products.
The company's Management, Supervisory Board and Scientific Advisory Board bring together an extensive know-how of genetics and the biotech and pharmaceutical industries. The company was founded in 1998 by scientists of the University of Amsterdam Medical Center (AMC).
Use of proceeds
AMT intends to use the proceeds of the IPO primarily for the development and commercialization of its products and to build a specialized marketing and sales team for Europe and North America capable of selling its lead product AMT-011 for LPL deficiency.
Details of the Offering
5,000,000 Offer Shares will be issued at a Final Offer Price of €10.00, subject to the satisfaction of certain conditions on the settlement date of the Offering (which is expected to be on 25 June 2007).
AMT has granted ABN AMRO Rothschild and Kempen & Co N.V. (the “Managers”) an over-allotment option exercisable within 30 calendar days after the first trading date pursuant to which the Managers may require AMT to issue up to 750,000 additional new ordinary shares (the “Additional Shares”, and together with the Offer Shares, the “Shares”) at the Final Offer Price to cover over-allotments made in connection with the Offering and short positions arising from stabilisation transactions (the “Over-Allotment Option”). ABN AMRO Bank N.V. will act as stabilisation agent on behalf of the Managers.
Immediately after completion of the Offering, AMT expects to have 14,680,493 ordinary shares outstanding (assuming full exercise of the Over-Allotment Option), of which 63.6% will be owned by Advent Venture Partners, Forbion Capital Partners, Gilde Healthcare Partners, Essential Medical Treatments AG, Crédit Agricole Private Equity and Amsterdam Medical Center (the “Major Shareholders”), excluding any Shares acquired by the Major Shareholders in the Offering.